Table 3 Patient demographics and baseline characteristics in AFM11-102
Safety population (n = 17) | |
|---|---|
Age (y), mean (SD) | 46.8 (18.80) |
Male, n (%) | 7 (41.2) |
Type of ALL, n (%) | |
CD19 + B-precursor Philadelphia-chromosome negative ALL | 16 (94.1) |
CD19 + B-precursor Philadelphia-chromosome positive ALL | 1 (5.9) |
Time since diagnosis (y), mean (SD) | 1.62 (1.11) |
Total number of relapses, mean (SD) | 1.6 (0.70) |
Previous treatments, n (%) | |
Chemotherapy | 17 (100) |
Targeted therapya | 3 (17.6) |
Radiotherapy | 3 (17.6) |
Peripheral blood stem cell transplant | 5 (29.4) |
Time from last treatment, n (%) | |
< 1 month | 6 (35.3) |
1 to < 3 months | 4 (23.5) |
3 to < 6 months | 1 (5.9) |
6 to < 12 months | 2 (11.8) |
≥ 12 months | 4 (23.5) |